Injectafer denied as duplicate or overlapping therapy by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for injectafer are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denied Injectafer as Duplicate Therapy

UnitedHealthcare (UHC) may issue a duplicate-therapy denial for Injectafer (ferric carboxymaltose) when its utilization management system identifies that another iron replacement product is already authorized or recently dispensed under the same benefit period, and determines that both are not simultaneously medically necessary. This denial is a coverage-logic determination, not a clinical one — but it is fully appealable when the prescriber can establish that Injectafer serves a distinct clinical function in this patient's case.

Injectafer has a distinct FDA-approved profile that may differ clinically from other iron products on the market. When the two therapies are not in fact interchangeable for a given patient, the duplicate-therapy characterization is challengeable with clinical documentation.

## Federal Appeal Framework

ACA §2719 entitles non-grandfathered plan members to a full internal appeal followed by external review by an accredited Independent Review Organization (IRO). ERISA §503 guarantees full-and-fair review for employer-sponsored plans, including the right to review the specific clinical criteria and evidence used. The external-review window is typically four months from the denial notice. Expedited review is available for clinically urgent situations and must be resolved within 72 hours.

## Concrete Appeal Steps

1. Request UHC's written denial documentation specifying which therapy it considers duplicative and the policy basis for that classification. 2. Have your prescriber confirm in writing whether the two products are clinically interchangeable for this patient — or why they are not. 3. Document any distinct clinical rationale: different iron formulations, routes, administration requirements, or FDA-label indications that are non-overlapping. 4. Submit the internal appeal to UHC within the plan's stated deadline (typically 180 days from denial notice). 5. Request a peer-to-peer review between your prescriber and UHC's medical director — this can accelerate resolution. 6. If the internal appeal is denied, file for external review within four months.

## Documentation to Gather

• Diagnosis confirmation: Current chart notes and labs establishing the diagnosis and clinical severity.
• Prior-therapy record: Documentation of the therapy UHC considers duplicative — dates, clinical response, and why it does not adequately substitute for Injectafer in this case.
• Prescriber clinical-distinction letter: Explains the specific clinical reason Injectafer is not a duplicate — referencing the FDA-approved prescribing label and any applicable clinical guideline organization.
• Clinical severity documentation: Objective notes demonstrating the patient's functional status and treatment urgency.

## Criteria-Mapping Structure

Obtain the FDA-approved Injectafer prescribing label and UHC's published medical/pharmacy coverage policy for IV iron replacement. Construct a table:

| UHC duplicate-therapy criterion | Rebuttal evidence | |---|---| | Both therapies treat same indication | [Prescriber letter distinguishing clinical role] | | Prior therapy adequate for this patient | [Prior-therapy dates, outcomes, documented inadequacy] | | Injectafer provides distinct clinical benefit | [FDA label reference + clinical rationale] |

An IRO reviewing a duplicate-therapy denial evaluates the clinical evidence independently and is not bound by UHC's internal formulary logic. A prescriber letter that precisely identifies the clinical distinction between the two agents is the cornerstone of this appeal.